Compound Summary
proglumide
Compound Information
proglumide
Compound Name: | proglumide |
Compound CID: | 4922 |
Synonyms: | proglumide 6620-60-6 4-benzamido-5-(dipropylamino)-5-oxopentanoic acid Binoside Xylamide More... |
Iupac Name: | 4-benzamido-5-(dipropylamino)-5-oxopentanoic acid |
InChI: | InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22) |
InChIKey: | DGMKFQYCZXERLX-UHFFFAOYSA-N |
Canonical Smiles: | CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1 |
Isomeric Smiles: | CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1 |
Molecular Weight: | 334.4 |
Molecular Formula: | C18H26N2O4 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
proglumide
Molecular Weight: | 334.4 |
Molecular Formula: | C18H26N2O4 |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 4 |
Rotatable Bond Count: | 10 |
Heavy Atom Count: | 24 |
Complexity: | 413 |
Synonyms
proglumide
| proglumide | proglumide |
|---|---|
proglumide |
6620-60-6 |
4-benzamido-5-(dipropylamino)-5-oxopentanoic acid |
Binoside |
Xylamide |
Proglumidum |
Proglumida |
Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo- |
W-5219 |
(+-)-4-Benzamido-N,N-dipropylglutaramic acid |
Nulsa |
Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+-)- |
CHEMBL316561 |
CHEBI:32058 |
dl-proglumide |
Milid |
4-(benzoylamino)-5-(dipropylamino)-5-oxopentanoic acid |
Gastrotopic |
Midelid |
Ulcutin |
Milide |
Xyde |
DSSTox_CID_3516 |
DSSTox_RID_77060 |
DSSTox_GSID_23516 |
Progumide |
Proglumidum INN-Latin |
Proglumida INN-Spanish |
Promide (parasympatholytic) |
CR 242 |
24485-90-3 |
Xylamide (gastroprotective agent) |
SR-01000002970 |
EINECS 229-567-4 |
242 DL |
W 5219 |
BRN 4151696 |
4-(N,N-dipropylcarbamoyl)-4-(phenylcarbonylamino)butanoic acid |
racemic proglumide |
(RS)-proglumide |
Proglumide,(S) |
Proglumide USAN:INN:BAN:JAN |
NCGC00016676-01 |
(+-)-proglumide |
Glutaramic acid, 4-benzamido-N,N-dipropyl-, DL- |
Prestwick_602 |
CAS-6620-60-6 |
CR-242 |
Nulsa (TN) |
Spectrum_001332 |
Prestwick0_000240 |
Prestwick1_000240 |
Prestwick2_000240 |
Prestwick3_000240 |
Spectrum2_001406 |
Spectrum3_001444 |
Spectrum4_000425 |
Spectrum5_001591 |
Lopac0_000832 |
SCHEMBL93339 |
BSPBio_000319 |
BSPBio_002907 |
GTPL893 |
KBioGR_000750 |
KBioSS_001812 |
MLS002154246 |
DivK1c_000684 |
SPECTRUM1501119 |
SPBio_001452 |
SPBio_002240 |
AMY374 |
BPBio1_000351 |
DTXSID7023516 |
Proglumide (JP17/USAN/INN) |
SCHEMBL19994752 |
CHEBI:76266 |
HMS502C06 |
KBio1_000684 |
KBio2_001812 |
KBio2_004380 |
KBio2_006948 |
KBio3_002407 |
AOB5334 |
NINDS_000684 |
HMS1568P21 |
HMS1921F19 |
HMS2092D13 |
HMS2095P21 |
HMS2235B24 |
HMS3262H05 |
HMS3369D14 |
HMS3712P21 |
Pharmakon1600-01501119 |
HY-B1330 |
Tox21_110557 |
Tox21_500832 |
BDBM50014888 |
CCG-39024 |
MFCD00055071 |
NSC757841 |
SBB058173 |
AKOS015895810 |
Tox21_110557_1 |
AC-1274 |
CS-8029 |
DB13431 |
KS-1212 |
LP00832 |
MCULE-2438450007 |
NSC 757841 |
NSC-757841 |
SDCCGSBI-0050809.P004 |
4-Benzamido-N,N-dipropylglutaramic acid |
IDI1_000684 |
N2-Benzoyl-N,N-dipropyl-alpha-glutamine |
NCGC00015623-03 |
NCGC00015623-04 |
NCGC00015623-05 |
NCGC00015623-06 |
NCGC00015623-07 |
NCGC00015623-10 |
NCGC00015623-14 |
NCGC00094163-01 |
NCGC00094163-02 |
NCGC00094163-03 |
NCGC00094163-04 |
NCGC00261517-01 |
BP166197 |
H786 |
SMR001233513 |
SBI-0050809.P003 |
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine |
AB00052206 |
EU-0100832 |
FT-0654938 |
M-001 |
ST51015098 |
N2-(phenylcarbonyl)-N,N-dipropyl-a-glutamine |
4-Benzoylamino-4-dipropylcarbamoyl-butyric acid |
D01818 |
rac-N(2)-benzoyl-N,N-dipropyl-alpha-glutamine |
AB00052206_08 |
4-Benzoylamino-5-dipropylamino-5-oxopentanoic acid |
620P606 |
N~2~-(phenylcarbonyl)-N,N-dipropyl-alpha-glutamine |
Q7248362 |
SR-01000002970-2 |
SR-01000002970-4 |
SR-01000002970-7 |
W-104770 |
4-(Benzoylamino)-5-(dipropylamino)-5-oxovaleric acid |
BRD-A44863528-001-05-8 |
BRD-A44863528-001-08-2 |
Experimental Data
proglumide
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 2.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
proglumide
Statistics Data
proglumide
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 2.000000000000000 | 1 | 1 |
Statistics Data Visualization
proglumide
